4/25
08:33 am
veru
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 [Yahoo! Finance]
Medium
Report
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 [Yahoo! Finance]
4/25
08:30 am
veru
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
Medium
Report
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
4/17
01:33 pm
veru
What Makes Veru (VERU) a New Buy Stock [Yahoo! Finance]
Medium
Report
What Makes Veru (VERU) a New Buy Stock [Yahoo! Finance]
4/15
08:11 am
veru
Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock, down previously from $7.00.
Low
Report
Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock, down previously from $7.00.
4/1
04:21 pm
veru
Veru Announces Date of 2024 Annual Meeting of Shareholders [Yahoo! Finance]
Low
Report
Veru Announces Date of 2024 Annual Meeting of Shareholders [Yahoo! Finance]
4/1
04:05 pm
veru
Veru Announces Date of 2024 Annual Meeting of Shareholders
Low
Report
Veru Announces Date of 2024 Annual Meeting of Shareholders
3/28
08:07 am
veru
Veru Inc. (NASDAQ: VERU) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock.
Low
Report
Veru Inc. (NASDAQ: VERU) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock.
3/22
04:17 pm
veru
Veru Reschedules Annual Meeting of Shareholders [Yahoo! Finance]
Medium
Report
Veru Reschedules Annual Meeting of Shareholders [Yahoo! Finance]
3/22
04:05 pm
veru
Veru Reschedules Annual Meeting of Shareholders
Medium
Report
Veru Reschedules Annual Meeting of Shareholders
3/12
08:17 am
veru
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss [Yahoo! Finance]
Medium
Report
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss [Yahoo! Finance]
3/12
08:00 am
veru
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Medium
Report
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
2/27
07:26 pm
veru
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q [Yahoo! Finance]
Low
Report
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q [Yahoo! Finance]
2/27
07:15 pm
veru
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Low
Report
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
2/20
08:38 am
veru
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss [Yahoo! Finance]
Low
Report
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss [Yahoo! Finance]
2/20
08:30 am
veru
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Medium
Report
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
2/13
11:18 am
veru
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU) [Yahoo! Finance]
Medium
Report
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU) [Yahoo! Finance]
2/9
10:59 am
veru
Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
2/8
03:36 pm
veru
Veru Inc. (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Low
Report
Veru Inc. (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
2/8
06:33 am
veru
Veru Reports Fiscal 2024 First Quarter Financial Highlights [Yahoo! Finance]
Medium
Report
Veru Reports Fiscal 2024 First Quarter Financial Highlights [Yahoo! Finance]
2/8
06:30 am
veru
Veru Reports Fiscal 2024 First Quarter Financial Highlights
Low
Report
Veru Reports Fiscal 2024 First Quarter Financial Highlights
2/6
08:46 am
veru
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs [Yahoo! Finance]
High
Report
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs [Yahoo! Finance]
2/6
08:30 am
veru
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
High
Report
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
2/1
12:12 pm
veru
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]
Medium
Report
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]
1/31
08:46 am
veru
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
1/31
08:30 am
veru
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference